Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 194
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2019  |  Volume : 24  |  Issue : 1  |  Page : 46

Transforming growth factor-β3 relation with osteoporosis and osteoporotic fractures


1 Department of Orthopedics, AJA University of Medical Sciences, Tehran, Iran
2 Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence Address:
Dr. Mostafa Shahrezaee
West Fatemi Street, Aja University of Medical Sciences, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jrms.JRMS_1062_18

Rights and Permissions

Background: The high socioeconomic impact of osteoporosis and osteoporotic fracture is due to their high mortality, morbidity, and disease-related costs. Nowadays, bone mineral density (BMD) is a comparatively expensive way to diagnose and follow up patients with osteoporosis. Transforming growth factor-β3 (TGF-β3) is a protein categorized into cytokines. Some previous in vitro studies showed TGF-β3 effects on osteocytes and bone formation. Therefore, we conducted this study to find if there is any significant relationship between TGF-β3 and BMD results. Materials and Methods: This was an analytical cross-sectional study conducted in 2017. We included individuals who had been referred from their physicians to undergo BMD dual-energy X-ray absorptiometry. Blood samples were taken from 150 participants for measuring TGF-β3 with ELISA method. Results: The mean ± standard deviation of TGF-β3 serum level was 79 ± 30.8 pg/ml (minimum 41 pg/ml and maximum 210 pg/ml). There was a statistically significant and direct proportional relationship between TGF-β3 and T-score as a marker for the diagnosis and follow-up of osteoporosis and osteoporotic fracture (P = 0.001) (Pearson's correlation = +0.95). Conclusion: There was a significant relationship between TGF-β3 serum level and BMD. TGF-β3 serum level may be used as a marker for the diagnosis and follow-up of osteoporosis and osteoporotic fracture.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed615    
    Printed57    
    Emailed0    
    PDF Downloaded126    
    Comments [Add]    

Recommend this journal